Bioethicist Slams 'Minimally Invasive' Brain Implant Marketing
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Anna Wexler, a medical ethics and health policy professor at the University of Pennsylvania Perelman School of Medicine, called the term "minimally invasive" "fuzzy" and "problematic," noting uncertainty over whether it refers to physical invasiveness.
- Brain-computer interface startups Synchron, Motif Neuroscience, Precision Neuroscience, and Merge Labs all use the phrase "minimally invasive" liberally on their websites to differentiate their devices from competitors.
- The fuzziness of the term has not stopped most BCI startups from deploying it in marketing, even as experts question its precision.
- Journalists sometimes repeat the marketing spin of "minimally invasive" without scrutiny, according to the source.
- Wexler said the term is "fraught," framing the marketing language as ethically murky for a category of devices still in development.
Why it matters: With four named BCI startups — Synchron, Motif Neuroscience, Precision Neuroscience, and Merge Labs — all leaning on the same vague phrase to stand out, patients weighing brain implants are getting marketing language rather than a standardized surgical-risk definition. A Penn bioethicist publicly flagging the term as "fraught" puts pressure on the field to clarify what "minimally invasive" actually means before devices reach broader clinical use.
Ask SkimNews
